Actinogen Medical FY21 Results- Progressing the Pipeline
Filed with ASX · · 4 pages · English
Key Highlights: • Demonstrated high levels of target occupancy in the brain for Xanamem daily doses ranging from 5mg to 30mg.A relatively flat dose response curve across all doses supports the exploration of doses as low as 5mg in future studies. • Commenced XanaMIA Phase 2 study for Alzheimer’s Disease. The cognition data collected through the successful Phase 1 XanaHES trial in healthy older pat
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen completes global patent family grant
- First Patient Enrolled in XanaMIA trial
- Actinogen receives positive Pre-IND FDA advice for FXS
- Clinical progress for XanaMIA trial
- Actinogen Ethics Committee approval for XanaMIA study
Later from Actinogen Medical
- R&D Tax Incentive Rebate received of A$1.435 million
- ACW announces open IND for Phase 2 Fragile X trial & LOI
- Program Expansion & Capital Raising
- Strategic Update & Capital Raising Investor Presentation
- XanaMIA Part A trial achieves target enrolment
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical